Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone - PubMed
5 hours ago
- #albuminuria reduction
- #combination therapy
- #eGFR changes
- The CONFIDENCE trial analyzed the effects of empagliflozin, finerenone, and their combination on eGFR and albuminuria in type 2 diabetes patients with CKD and albuminuria.
- Acute eGFR decline was greater with combination therapy than monotherapies, especially in participants with higher baseline eGFR and those on diuretics; these changes were reversible.
- Acute eGFR changes mediated 28% of the UACR reduction when adding empagliflozin to finerenone, but only 5.2% when adding finerenone to empagliflozin, indicating non-hemodynamic mechanisms for finerenone's additive effect.
- Acute kidney injury was uncommon across all treatment groups, and baseline systolic BP and UACR did not significantly affect acute eGFR decline.